Abstract 1324
Background
Tumour markers are widely used for screening and monitoring cancers. CA 15-3 and CEA are FDA-approved tumour markers for monitoring breast cancer. However, the prognostic efficacy of preoperative elevation of CEA and CA15-3 levels in breast cancer remains controversial.
Methods
We retrospectively analyzed the clinicopathological parameters and preoperative serum CEA and CA 15-3 level of 149,238 patients of Korean Breast Cancer Society Registry (KBCSR) Database who underwent surgery between January 2000 and December 2015.
Results
The patients with elevated CA 15-3/CEA level had shown more advanced T stage and N stage, ER negativity, PR negativity and HER2 positivity compared the patients with normal CA15-3/CEA levels. The patients with elevated CA 15-3/CEA level had worse OS than the patients with normal CA 15-3/CEA level. In survival analysis, both elevated group had worst prognosis compared other groups. In subgroup analysis by subtypes, in luminal A, both elevated group had hazard ratio (HR) 2.14 (95% CI 1.01-4.55), only CA 15-3 elevated had HR 2.38 (95% CI 1.58-3.58) and only CEA elevated group had HR 1.79 (95% CI, 1.20-2.68), compared normal group. In luminal B, both elevated group had HR 3.99 (95% CI 2.23-7.16), only CA 15-3 elevated had HR 2.38 (95% CI 1.58-3.58) and only CEA elevated group had HR 1.79 (95% CI, 1.20-2.68), compared normal group. In HER2 subtype group, elevated CEA level was the only independent prognostic factor. However, in TNBC, elevated preoperative CEA and CA 15-3 level were not a significant prognostic factor for OS.
Conclusions
The elevation of preoperative tumor markers was associated with aggressive characteristic and worse overall survival. Preoperative tumor markers predicted the prognosis of the patients and showed differences according to subtypes. In luminal breast cancer, the CA 15-3 elevation has higher hazard ratio than the CEA elevation and the patients with both tumor markers showed the worst prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5458 - Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120 mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen.
Presenter: Philippe Ruszniewski
Session: Poster Display session 2
Resources:
Abstract
1234 - Analysis of PD-1/PD-L1 blockade biomarker and immune infiltrates in Gastroenteropancreatic neuroendocrine carcinoma
Presenter: Jia Zhang Xing
Session: Poster Display session 2
Resources:
Abstract
1517 - Diabetes Is Associated With Pancreatic Neuroendocrine Tumors Growth and Metastasis
Presenter: Zhiyao Fan
Session: Poster Display session 2
Resources:
Abstract
2145 - Investigation of the reclassification of G1/G2 pancreatic neuroendocrine neoplasms by WHO 2017 classification
Presenter: Takahiro Yokose
Session: Poster Display session 2
Resources:
Abstract
3134 - Treatment with somatostatin analogues after radiopeptide therapy
Presenter: Daria Handkiewicz Junak
Session: Poster Display session 2
Resources:
Abstract
2191 - Safety and Tolerability of Surufatinib in Western Patients with Solid Tumors
Presenter: Erika Hamilton
Session: Poster Display session 2
Resources:
Abstract
3253 - The impact of tumour absorbed dosimetry with survival outcomes after peptide receptor radionuclide therapy in metastatic neuroendocrine tumours.
Presenter: Rahul Ladwa
Session: Poster Display session 2
Resources:
Abstract
3581 - Opportunist and Serious Infections in Patients with Neuroendocrine Tumors Treated With Everolimus: A Multicenter Study of Real World Patients
Presenter: Carine Mauro
Session: Poster Display session 2
Resources:
Abstract
5374 - Establishment of Prognostic Nomogram Based on the Metastatic Lymph Nodes Ratio for Patients with Gastric Neuroendocrine Tumour
Presenter: yaobin lin
Session: Poster Display session 2
Resources:
Abstract
3951 - Neutrophil-lymphocyte ratio as an independent predictive factor in Neuroendocrine Neoplasms
Presenter: Sofia Ferreira
Session: Poster Display session 2
Resources:
Abstract